StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. The company is headquartered in Richmond Hill, Ontario and currently employs 40 full-time employees. The company is developing and commercializing proprietary molecular diagnostic tests for early detection of diseases and for personalized health management, with an initial focus on cancer-related indications. The firm offers early cancer diagnostics and risk stratification via Aristotle, using messenger Ribonucleic Acid (mRNA) technology to identify the molecular signatures of multiple cancer types. Its Care Oncology Clinic provides the COC Protocol, a supervised treatment regimen designed to target multiple metabolic cancer pathways, complementing standard cancer therapies by limiting cancer cell energy supply and use. Additionally, COC offers AVRT, a physician-led telehealth program dedicated to identifying and managing early warning signs of cancer and chronic diseases.
根據最新的財務報表(Form-10K),StageZero Life Sciences Ltd 的總資產為 $0,淨損失為 $-11
SZLSF 的關鍵財務比率是什麼?
StageZero Life Sciences Ltd 的流動比率為 0,淨利潤率為 -366.66,每股銷售為 $0.02。
StageZero Life Sciences Ltd 的收入按細分市場或地理位置如何劃分?
StageZero Life Sciences Ltd 最大收入來源為 TV Media Resources Management,在最近的收益報告中收入為 371,674,117。就地區而言,China 是 StageZero Life Sciences Ltd 的主要市場,收入為 655,252,875。
StageZero Life Sciences Ltd 是否盈利?
無,根據最新的財務報表,StageZero Life Sciences Ltd 的淨損失為 $-11